Clinical data | |
---|---|
Trade names | Yorvipath |
Other names | ACP-014, TransCon PTH |
Routes of administration | Subcutaneous |
Drug class | Hormonal agent |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Palopegteriparatide, sold under the brand name Yorvipath, is a hormone replacement therapy used for the treatment of chronic hypoparathyroidism. [1] It is a transiently pegylated parathyroid hormone. [3]
Yorvipath indicated for the treatment of adults with chronic hypoparathyroidism. [1]
In September 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Yorvipath, intended for the treatment of chronic hypoparathyroidism in adults. [3] [4] The applicant for this medicinal product is Ascendis Pharma Bone Diseases A/S. [3] Palopegteriparatide was approved for medical use in the European Union in November 2023. [1]
Palopegteriparatide was granted an orphan drug designation by the US Food and Drug Administration (FDA) in 2018, [5] and by the EMA in 2020. [6]
Palopegteriparatide is the international nonproprietary name. [7] [8]
Palopegteriparatide is sold under the brand name Yorvipath. [1]
Clinical data | |
---|---|
Trade names | Yorvipath |
Other names | ACP-014, TransCon PTH |
Routes of administration | Subcutaneous |
Drug class | Hormonal agent |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Palopegteriparatide, sold under the brand name Yorvipath, is a hormone replacement therapy used for the treatment of chronic hypoparathyroidism. [1] It is a transiently pegylated parathyroid hormone. [3]
Yorvipath indicated for the treatment of adults with chronic hypoparathyroidism. [1]
In September 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Yorvipath, intended for the treatment of chronic hypoparathyroidism in adults. [3] [4] The applicant for this medicinal product is Ascendis Pharma Bone Diseases A/S. [3] Palopegteriparatide was approved for medical use in the European Union in November 2023. [1]
Palopegteriparatide was granted an orphan drug designation by the US Food and Drug Administration (FDA) in 2018, [5] and by the EMA in 2020. [6]
Palopegteriparatide is the international nonproprietary name. [7] [8]
Palopegteriparatide is sold under the brand name Yorvipath. [1]